摘要
2019年9月20日,诺和诺德公司研发的索马鲁肽口服制剂(每日1次)在美国上市,这是首个上市的胰高糖素样肽-1受体激动剂(GLP-1RA)口服制剂,这大大增加2型糖尿病患者使用GLP-1RA的便捷性与依从性。本文将重点从索马鲁肽口服制剂的疗效、药物相互作用、心肝肾功能不全患者的注意事项等方面,来阐述索马鲁肽口服剂的研究进展。
On September 20th 2019,Novo Nordisk announced official approval on the market of its new drug-oral tablet semaglutide,which would the first once-daily oral glucagon-like peptide-1 receptor agonist(GLP-1RA)and affiliate the convenience and compliance of patients with type 2 diabetes in clinics.This review would focus on the efficacy,drug interaction and indication for patients with heart,renal or hepatic insufficiency by oral semaglutide.
作者
李艳梅
唐祎偌
夏旋
LI Yan-mei;TANG Yi-ruo;XIA Xuan(Department of Physiology and Pathophysiology,College of Medical Sciences,China Three Gorges University,Yichang Hubei 443002,China)
出处
《药品评价》
CAS
2019年第24期1-3,5,共4页
Drug Evaluation
基金
湖北省自然科学基金面上项目(2015CFB316)资助
